Tags : PH1

Alnylam Initiates P-III ILLUMINATE-B Study of Lumasiran for Primary Hyperoxaluria

Tuba Khan April 16, 2019

Shots: The P-III ILLUMINATE-B study will assess Lumasiran in 8 patients with primary hyperoxaluria type 1 (PH1) aged < 6yrs., associated 1EPs as reduction of urinary oxalate in 6mos. & […]readmore

Tags : PH1

Alnylam Initiates P-III ILLUMINATE-B Study of Lumasiran for Primary Hyperoxaluria

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : PH1

Alnylam Initiates P-III ILLUMINATE-B Study of Lumasiran for Primary Hyperoxaluria

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company